en_US EN
en_US EN ro_RO RO sr_RS SR pt_PT PT mk_MK MK
References – PAGE, Module 2
  1. United Nations Office on Drugs and Crime. What are NPS? — How widespread are NPS? Early Warning Advisory on New Psychoactive Substances. 2024 [cited 2025 Sep 19]. Available from: https://www.unodc.org/LSS/Page/NPS
  2. What are new psychoactive substances? Available from: https://www.youtube.com/watch?v=7jF6S6YNC3U&list=PLVoVaLKfvFDB7bnSsnKj9aLFEC2h3xB8f&index=1 
  3. European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances: health and social responses [mini-guide]. Luxembourg: Publications Office of the European Union; 2021 Oct 26. Available From: https://www.euda.europa.eu/publications/mini-guides/new-psychoactive-substances-health-and-social-responses_en
  4. United Nations. Single Convention on Narcotic Drugs, 1961. New York: United Nations; 1961. Available from: https://www.unodc.org/unodc/en/commissions/CND/conventions.html
  5. United Nations. Convention on Psychotropic Substances, 1971. New York: United Nations; 1971. Available from: https://www.unodc.org/unodc/en/commissions/CND/conventions.html
  6. United Nations. United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988. New York: United Nations; 1988. Available from: https://www.unodc.org/unodc/en/commissions/CND/conventions.html
  7. World Health Organization. Expert Committee on Drug Dependence (ECDD). Geneva: WHO; 2024 [cited 2025 Sep 19]. Available from: https://www.who.int/groups/who-expert-committee-on-drug-dependence-(ecdd)
  8. Council of the European Union. Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new psychoactive substances. Official Journal of the European Union. 2005 May 20;(L 127):32-7. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32005D0387
  9. European Union Drugs Agency (EUDA). European Early Warning System (EWS) on new psychoactive substances. Lisbon: EUDA; 2024 [cited 2025 Sep 19]. Available from: https://www.euda.europa.eu/activities/eu-early-warning-system-on-nps_en
  10. European Parliament, Council of the European Union. Regulation (EU) 2017/2101 of the European Parliament and of the Council of 15 November 2017 amending Regulation (EC) No 1920/2006 as regards information exchange on, and an early warning system and risk assessment procedure for, new psychoactive substances. Official Journal of the European Union. 2017 Nov 22;(L 305):1–7. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R2101
  11. European Monitoring Centre for Drugs and Drug Addiction (now EUDA). European Drug Report 2018: Trends and Developments. Luxembourg: Publications Office of the European Union; 2018. Available from: https://www.emcdda.europa.eu/publications/edr/trends-developments/2018_en
  12. European Monitoring Centre for Drugs and Drug Addiction. Legal approaches to controlling new psychoactive substances. Luxembourg: Publications Office of the European Union; 2016. Available from: https://www.emcdda.europa.eu/publications/insights/legal-approaches-to-controlling-nps_en
  13. Home Office (UK). Psychoactive Substances Act 2016. London: The Stationery Office; 2016. Available from: https://www.legislation.gov.uk/ukpga/2016/2/contents/enacted
  14. German Federal Ministry of Health. New Psychoactive Substances Act (NpSG). Berlin: Bundesministerium für Gesundheit; 2016. Available from: https://www.gesetze-im-internet.de/npsg/
  15. Irish Government. Criminal Justice (Psychoactive Substances) Act 2010. Dublin: Government of Ireland; 2010. Available from: https://www.irishstatutebook.ie/eli/2010/act/22/enacted/en/html
  16. Adley M. The Drugs Wheel: a new approach to drug education. The Drugs Wheel. 2012 [cited 2025 Sep 19]. Available from: https://www.thedrugswheel.com
  17. Shafi A, Berry AJ, Sumnall H, Wood DM, Tracy DK. New psychoactive substances: a review and updates. Therapeutic Advances in Psychopharmacology. 2020 Dec 17;10:2045125320967197. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750892/
  18. PsychonautWiki. Synthetic cannabinoid [Internet]. PsychonautWiki; [cited 2025 Sep 19]. Available from: https://psychonautwiki.org/wiki/Synthetic_cannabinoid
  19. Alcohol and Drug Foundation. Synthetic cannabinoids [Internet]. Melbourne: Alcohol and Drug Foundation; 2025 Jun 6 [cited 2025 Sep 19]. Available from: https://adf.org.au/drug-facts/synthetic-cannabinoids/
  20. European Union Drugs Agency. New psychoactive substances – the current situation in Europe (European Drug Report 2024) [Internet]. Lisbon: EUDA; 2024 [cited 2025 Sep 19]. Available from: https://www.euda.europa.eu/publications/european-drug-report/2024/new-psychoactive-substances_en
  21. Oomen P, Schori D, Tögel-Lins K, Acreman D, et al. Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services. International Journal of Drug Policy. 2022;100:103493. https://pubmed.ncbi.nlm.nih.gov/34687992/
  22. Monti MC, Zeugin J, Koch K, Milenkovic N, Scheurer E, Mercer-Chalmers-Bender K. Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services. Drug Testing and Analysis. 2022;14(6):1026-39. doi:10.1002/dta.3220.
  23. Cohen K, Weinstein AM. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Perspective. Frontiers in Public Health. 2018;6:162. doi:10.3389/fpubh.2018.00162  https://pubmed.ncbi.nlm.nih.gov/29930934/
  24. European Monitoring Centre for Drugs and Drug Addiction. Synthetic cathinones in Europe. Lisbon: EMCDDA; 2018. Available from: https://www.emcdda.europa.eu/publications/rapid-communications/2018/synthetic-cathinones-in-europe_en
  25. Prekupec MP, Mansky PA, Baumann MH. Misuse of novel synthetic opioids: a deadly new trend. J Addict Med. 2017;11(4):256-65. doi:10.1097/ADM.0000000000000324. available from: https://pubmed.ncbi.nlm.nih.gov/28590391/
  26. Tsang VWL, Wong JSH, Westenberg JN, Ramadhan NH, Fadakar H, Nikoo M, et al. Systematic review on intentional non-medical fentanyl use among people who use drugs. Front Psychiatry. 2024;15:1347678. doi:10.3389/fpsyt.2024.1347678. Aailable from: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1347678/full
  27. Correlation – European Harm Reduction Network. Webinar | Nitazenes in Europe – How Should We Prepare?[Internet]. YouTube; 2025 Mar 31 [cited 2025 Sep 19]. Available from: https://www.youtube.com/watch?v=_OwJDkcB79M
  28. Griffiths PN, Seyler T, De Morais JM, Mounteney JE, Sedefov RS. Opioid problems are changing in Europe with worrying signals that synthetic opioids may play a more significant role in the future. Addiction. 2024;119(8):1334-6. doi:10.1111/add.16420 Available from: https://onlinelibrary.wiley.com/doi/10.1111/add.16420
  29. Alcohol and Drug Foundation. Fentanyl [Internet]. Australia: Alcohol and Drug Foundation; 2025 Jun 06 [cited 2025 Sep 29]. Available from: https://adf.org.au/drug-facts/fentanyl/
  30. ESPAD Group. ESPAD report 2023: Results from the European School Survey Project on Alcohol and Other Drugs [Internet]. Luxembourg: Publications Office of the European Union; 2023 [cited 2025 Sep 29]. Available from: https://www.espad.org
  31. Hondebrink L, Nugteren-van Lonkhuyzen JJ, Van Der Gouwe D, Brunt TM. New psychoactive substances (NPS) in the Netherlands: occurrence in forensic drug samples, consumer use, and public health incidents. Forensic Toxicol. 2020;38(2): 294-306. Available from: https://onlinelibrary.wiley.com/doi/10.1111/add.14868
  32. Hibell B, Guttormsson U, Ahlström S, Balakireva O, Bjarnason T, Kokkevi A, et al. The 2015 ESPAD report: Results from the European School Survey Project on Alcohol and Other Drugs [Internet]. Luxembourg: Publications Office of the European Union; 2016 [cited 2025 Sep 29]. Available from: https://www.espad.org/espad-report-2015
  33. Palamar JJ, Acosta P, Sherman S, Ompad DC, Cleland CM. Correlates of new psychoactive substance use among a self-selected sample of nightlife attendees in New York City. Am J Drug Alcohol Abuse. 2016;42(6):665-75. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5072356/
  34. Benschop A, van Havere T, Rosiers J, Philippens M, Hardon A, Koeter M, et al. Why do people use new psychoactive substances? A qualitative study of self-reported motivations, user characteristics, and contexts of use. Int J Drug Policy. 2019;71:124-31.
  35. Scottish Government. Understanding patterns of use, motives & harms of new psychoactive substances: motives for NPS use [Internet]. Edinburgh: Scottish Government; 2015 [cited 2025 Sep 29]. Available from: https://www.gov.scot/publications/understanding-patterns-use-motives-harms-new-psychoactive-substances-scotland/pages/9/
  36. Soussan C, Kjellgren A. The diverse reasons for using Novel Psychoactive Substances (NPS): a qualitative, user-driven exploration. Int J Drug Policy. 2018;55:77–84. Available from: ScienceDirect
  37. Van Hout MC, Bingham T. New psychoactive substances on cryptomarket fora: darknet market supply of NPS and the role of social provisioning. Int J Drug Policy. 2017; 41: 77–87. ScienceDirect
  38. Van der Sanden R, Pardo B, Barratt M, et al. Social Supply and the Potential for Harm Reduction in the Intersection Between Darknet Markets and Local Social Media-Facilitated Supply. J Drug Issues. 2023;53(5): 610–29.
  39. Johnston, L. D., O’Malley, P. M., Miech, R. A., Bachman, J. G., & Schulenberg, J. E. (2015). Monitoring the Future national survey results on drug use: 1975-2014: Overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan. Available from: https://monitoringthefuture.org/wp-content/uploads/2022/08/mtf-overview2014.pdf
  40. Corazza O, Coloccini S, Marrinan S, Brosnan L, Purkiss C, Stair J, et al. Novel psychoactive substances in custodial settings: a mixed-method investigation on the experiences of people in prison and professionals working with them. Front Psychiatry. 2020;11:460. doi:10.3389/fpsyt.2020.00460. available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7264108/
  41. Public Health England, Department of Health and Social Care. Alcohol and drug treatment in secure settings 2018 to 2019: report [Internet]. London: Public Health England; 2019 [cited 2025 Sep 29]. Available from: https://www.gov.uk/government/statistics/substance-misuse-treatment-in-secure-settings-2018-to-2019/alcohol-and-drug-treatment-in-secure-settings-2018-to-2019-report
  42. Montanari L, Penna V, Inciardi R, Brugal MT, Puro KM, Cogliati Dezza F, et al. Towards better prepared prisons: monitoring and response to emerging drug challenges in European correctional settings. Front Psychiatry. 2024;15:11517710. doi:10.3389/fpsyt.2024.11517710. Available from: https://academic.oup.com/eurpub/article/34/Supplement_3/ckae144.674/7844778
  43. Chiappini S, Vaccaro G, Mosca A, Miuli A, Stigliano G, Stefanelli G, et al. New trends of drug abuse in custodial settings: a systematic review on the misuse of over-the-counter drugs, prescription-only-medications, and new psychoactive substances. Neurosci Biobehav Rev. 2024;162:105691. doi:10.1016/j.neubiorev.2024.105691 available from: https://www.sciencedirect.com/science/article/pii/S014976342400160X?via%3Dihub
  44. European Monitoring Centre for Drugs and Drug Addiction. Prison and drugs in Europe: current and future challenges [Internet]. Lisbon: EMCDDA; 2021 Jun 25 [cited 2025 Sep 29]. Available from: https://www.euda.europa.eu/publications/insights/prison-and-drugs-in-europe_en euda.europa.eu+1
  45. Bourne, A., Reid, D., Hickson, F., Torres-Rueda, S., Steinberg, P., & Weatherburn, P. (2015). Chemsex and harm reduction need among gay men in South London. International Journal of Drug Policy, 26(12), 1171–1176. https://doi.org/10.1016/j.drugpo.2015.07.013 
  46. Maxwell, S., Shahmanesh, M., & Gafos, M. (2019). Chemsex behaviours among men who have sex with men: A systematic review of the literature. International Journal of Drug Policy, 63, 74–89. https://doi.org/10.1016/j.drugpo.2018.11.014 
  47. Edmundson, C., Heinsbroek, E., Glass, R., Hope, V., Mohammed, H., White, M., & Desai, M. (2018). Sex, drugs and smart phone applications: Findings from semistructured interviews with men who have sex with men diagnosed with Shigella flexneri 3a in England and Wales. Sexually Transmitted Infections, 94(4), 241–246. https://doi.org/10.1136/sextrans-2017-053268 
  48. Schmidt, A. J., Bourne, A., Weatherburn, P., Reid, D., Marcus, U., Hickson, F., & EMIS Network. (2016). Illicit drug use among gay and bisexual men in 44 cities: Findings from the European MSM Internet Survey (EMIS). International Journal of Drug Policy, 38, 4–12. https://doi.org/10.1016/j.drugpo.2016.09.007 
  49. EMCDDA. (2022). Chemsex: Health responses in Europe. Publications Office of the European Union. https://www.emcdda.europa.eu/publications/health-responses/chemsex-health-responses-in-europe_en 
  50. Fernández-Dávila, P., Salazar, X., & Folch, C. (2021). Slamming among men who have sex with men in Spain: Prevalence and associated factors. AIDS and Behavior, 25(11), 3674–3685. https://doi.org/10.1007/s10461-021-03262-8 
  51. Hockenhull, J., Murphy, K. G., & Paterson, S. (2017). An observed rise in γ-hydroxybutyrate-associated deaths in London: Evidence of a possible epidemic. British Journal of Clinical Pharmacology, 83(5), 1033–1040. https://doi.org/10.1111/bcp.13210